Algernon Pharmaceuticals Inc.
AGN
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 50.74% | -51.07% | -5.25% | -56.05% | -44.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.16% | -67.07% | -30.37% | -61.18% | -58.55% |
| Operating Income | -19.16% | 67.07% | 30.37% | 61.18% | 58.55% |
| Income Before Tax | -139.15% | 65.19% | 27.49% | 83.77% | 227.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.15% | 65.19% | 27.49% | 83.77% | 227.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.15% | 65.19% | 27.49% | 83.77% | 227.54% |
| EBIT | -19.16% | 67.07% | 30.37% | 61.18% | 58.55% |
| EBITDA | -18.90% | 67.39% | 30.41% | 61.19% | 58.63% |
| EPS Basic | -129.42% | 75.58% | 58.26% | 78.88% | 164.97% |
| Normalized Basic EPS | 9.18% | 75.31% | 58.28% | -199.34% | 79.06% |
| EPS Diluted | -132.50% | 75.58% | 58.26% | 79.05% | 158.82% |
| Normalized Diluted EPS | 9.18% | 75.31% | 58.28% | -199.34% | 79.06% |
| Average Basic Shares Outstanding | 33.34% | 42.07% | 73.06% | -22.93% | 96.22% |
| Average Diluted Shares Outstanding | 33.34% | 42.07% | 73.06% | -22.93% | 96.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |